GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes with CKD stages 2-4: a target trial emulation
In brief
In CKD, GLP-1 drugs linked to 21% lower mortality over 3 years
In a matched cohort of 28,824 patients per group with type 2 diabetes and chronic kidney disease, those starting GLP-1 drugs had 16% lower risk of major kidney events, 12% lower cardiovascular risk and 21% lower mortality than those starting DPP-4 inhibitors over 3 years. Hypoglycemia rates were similar, but this real-world study cannot prove the drugs caused the lower risks.
- Journal
- Diabetology & metabolic syndrome (Q1)
- Published
- 11 August 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Yung-Chih Chen, Solomon Chih-Cheng Chen
- PMID
- 43000411
- DOI
- 10.1186/s13098-026-02266-1
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 13 November 2026): Comparative cardiorenal outcomes in diabetes with CKD inform multimorbidity care
Abstract
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) face compounded cardiorenal risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular and renal benefits in randomized trials, yet real-world evidence in populations with established CKD stages 2 through 4 remains limited. We aimed to compare cardiorenal outcomes between new users of GLP-1 RAs and dipeptidyl peptidase-4 inhibitors (DPP-4i) in this high-risk population. METHODS: Using the TriNetX Global Collaborative Network, we conducted a new-user, active-comparator cohort study emulating a target trial. Adults with T2DM and CKD stages 2-4 who initiated GLP-1 RA or DPP-4i between January 2017 and December 2021 were identified. After 1:1 propensity score matching on 40 covariates, 28,824 patients per group were retained. Three co-primary outcomes-MAKE, MACE, and all-cause mortality-were assessed at 1, 2, and 3 years from the same matched cohort. Secondary outcomes included a safety composite and hypoglycemia. Conjunctivitis served as a negative control outcome. Restricted mean survival time was calculated as a supplementary analysis. RESULTS: At 3 years, GLP-1 RA initiation was associated with significantly lower risks of MAKE (hazard ratio [HR] 0.837; 95% confidence interval [CI] 0.796-0.880; P < .001), MACE (HR 0.875; 95% CI 0.843-0.909; P < .001), and all-cause mortality (HR 0.787; 95% CI 0.743-0.834; P < .001) compared with DPP-4i. These associations were evident at 1 year and persisted through 3 years. The safety composite favored GLP-1 RAs (HR 0.905; 95% CI 0.877-0.934; P < .001), with comparable hypoglycemia rates between groups. The negative control outcome yielded null results (HR 0.959; 95% CI 0.865-1.065; P = .436), supporting the validity of the study design. CONCLUSIONS: In this large, propensity score-matched, international real-world cohort, GLP-1 RA initiation was associated with significantly lower risks of adverse kidney events, cardiovascular events, and mortality compared with DPP-4i in patients with T2DM and CKD stages 2 through 4. Benefits emerged early and persisted over 3 years, providing supportive evidence for GLP-1 RAs to a population underrepresented in randomized trials.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.